MX2022004712A - Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5. - Google Patents
Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5.Info
- Publication number
- MX2022004712A MX2022004712A MX2022004712A MX2022004712A MX2022004712A MX 2022004712 A MX2022004712 A MX 2022004712A MX 2022004712 A MX2022004712 A MX 2022004712A MX 2022004712 A MX2022004712 A MX 2022004712A MX 2022004712 A MX2022004712 A MX 2022004712A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- preventing
- associated diseases
- dosing regimens
- pozelimab
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención proporciona regímenes de dosificación de anticuerpos anti-C5, tal como pozelimab, para tratar o prevenir enfermedades asociadas a C5, tal como la hemoglobinuria paroxística nocturna o la enfermedad CHAPLE.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962926213P | 2019-10-25 | 2019-10-25 | |
US202062992330P | 2020-03-20 | 2020-03-20 | |
US202063019533P | 2020-05-04 | 2020-05-04 | |
PCT/US2020/056981 WO2021081277A1 (en) | 2019-10-25 | 2020-10-23 | Dosing regimens for treating or preventing c5-associated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022004712A true MX2022004712A (es) | 2022-08-04 |
Family
ID=73449214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022004712A MX2022004712A (es) | 2019-10-25 | 2020-10-23 | Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210139573A1 (es) |
EP (1) | EP4048691A1 (es) |
JP (1) | JP2022553377A (es) |
KR (1) | KR20220087537A (es) |
CN (1) | CN115052889A (es) |
AU (1) | AU2020369581A1 (es) |
CA (1) | CA3153195A1 (es) |
IL (1) | IL291807A (es) |
MX (1) | MX2022004712A (es) |
WO (1) | WO2021081277A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023077053A2 (en) | 2021-10-28 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
EP1520022B1 (en) | 2002-07-10 | 2015-07-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna-interference by single-stranded rna molecules |
ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
DK2279254T3 (en) | 2008-04-15 | 2017-09-18 | Protiva Biotherapeutics Inc | PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION |
EP2837388A1 (en) | 2008-08-05 | 2015-02-18 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
KR102205886B1 (ko) | 2009-06-10 | 2021-01-21 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
SG11201507400SA (en) | 2013-03-14 | 2015-10-29 | Alnylam Pharmaceuticals Inc | Complement component c5 irna compositions and methods of use thereof |
US20190225678A1 (en) * | 2016-06-07 | 2019-07-25 | Novartis Ag | Anti-c5 antibody for treating patients with complement c5 polymorphism |
CA3027487A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
US20190256915A1 (en) * | 2016-09-14 | 2019-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Methods of diagnosing and treating cd55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (chaple), a newly identified orphan disease |
JP6383122B2 (ja) * | 2017-01-31 | 2018-08-29 | 中外製薬株式会社 | C5関連疾患の治療または予防用の医薬組成物およびc5関連疾患を治療または予防するための方法 |
-
2020
- 2020-10-23 IL IL291807A patent/IL291807A/en unknown
- 2020-10-23 KR KR1020227017548A patent/KR20220087537A/ko unknown
- 2020-10-23 US US17/078,309 patent/US20210139573A1/en active Pending
- 2020-10-23 WO PCT/US2020/056981 patent/WO2021081277A1/en unknown
- 2020-10-23 EP EP20807598.6A patent/EP4048691A1/en active Pending
- 2020-10-23 CA CA3153195A patent/CA3153195A1/en active Pending
- 2020-10-23 AU AU2020369581A patent/AU2020369581A1/en active Pending
- 2020-10-23 CN CN202080089231.8A patent/CN115052889A/zh active Pending
- 2020-10-23 JP JP2022523875A patent/JP2022553377A/ja active Pending
- 2020-10-23 MX MX2022004712A patent/MX2022004712A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN115052889A (zh) | 2022-09-13 |
WO2021081277A1 (en) | 2021-04-29 |
JP2022553377A (ja) | 2022-12-22 |
IL291807A (en) | 2022-06-01 |
EP4048691A1 (en) | 2022-08-31 |
AU2020369581A1 (en) | 2022-04-21 |
US20210139573A1 (en) | 2021-05-13 |
CA3153195A1 (en) | 2021-04-29 |
KR20220087537A (ko) | 2022-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500177A1 (en) | Bcma monoclonal antibody-drug conjugate | |
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
MX2022005253A (es) | Anticuerpos neutralizantes de poliomavirus. | |
EA201800444A1 (ru) | Производные майтанзиноида, их конъюгаты и способы использования | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
MY199530A (en) | Anti-cd3epsilon antibodies | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
CY1123275T1 (el) | Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων | |
MX2020008122A (es) | Anticuerpos anti-pd-1. | |
BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
TN2019000106A1 (en) | Novel compounds for treating parasitic disease | |
EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека | |
EA202192786A1 (ru) | Твердые формы (e)-3-[2-(2-тиенил)винил]-1h-пиразола | |
EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
MX2021006515A (es) | Composiciones de methylobacterium para mejorar el rendimiento del maíz. | |
MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. | |
MX2022004712A (es) | Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5. | |
CR20220228A (es) | Anticuerpos trem2 y usos de estos | |
CR20220006A (es) | Compuestos para tratar enfermedad respiratoria | |
EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
MX2020010092A (es) | Variantes de anticuerpo c-terminales. | |
MX2017002093A (es) | Terapia con anticuerpos para vih como sustituto de tratamiento. |